Smoking-linked cadmium switches on a brain signal that damages neuronal mitochondria — in human data and lab-grown neurons

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Epidemiology can point at a toxin for decades without ever naming the wire it pulls inside a neuron. This study tries to name the wire — a stress kinase that sits, suspiciously, at the junction of amyloid and the mitochondrion's first energy complex.

How did the team connect smoking, cadmium and a brain gene?

The study is a layered triangulation. First, survey-weighted NHANES data established the exposure link in the general population: ever-smoking was associated with higher whole-blood cadmium concentrations. Second, transcriptomic and single-nucleus analyses of brain data searched for the molecular meeting point, and highlighted c-Jun N-terminal kinase 2 (JNK2), encoded by MAPK9, as the candidate gene — enriched in excitatory neurons, with heightened cell communication and a link to amyloid-beta-associated mitochondrial complex I dysfunction. Third came validation: in human brain, JNK2 phosphorylation was increased in Alzheimer's disease, and in neurons, cadmium chloride elevated JNK2 phosphorylation and APP protein abundance and impaired mitochondria. Each layer is a different kind of evidence — population association, computational nomination, tissue and cell validation — and the paper's strength is that the layers point at the same node.

Why do mitochondria sit at the center of it?

Complex I is the entry gate of the electron transport chain — the first and largest machine in the mitochondrial energy assembly line — and its dysfunction is a recurring finding in Alzheimer's research. Here, the single-nucleus signal tied MAPK9/JNK2 activity in excitatory neurons specifically to amyloid-beta-linked complex I dysfunction, and the cell experiments showed cadmium exposure impairing mitochondria while raising APP, the precursor from which amyloid-beta is cut. That sketches a feed-forward loop worth testing: exposure activates a stress kinase; the kinase's neuronal context intersects both amyloid production and mitochondrial failure; each of those is independently known to worsen the other. The study demonstrates the components and their cadmium responsiveness in models — it does not demonstrate the full loop operating in a living human brain.

What about sanguinarine — and what should readers not conclude?

The paper's most speculative element is its candidate compound: molecular docking and dynamics simulations supported sanguinarine, a plant alkaloid, binding MAPK9 stably, and the authors report it mitigating mitochondrial dysfunction in their experimental models, nominating it as a candidate for targeting the pathway. Docking is a computational prediction, sanguinarine has its own toxicity history, and nothing here is a prevention or treatment recommendation. The firmer conclusions are the negative-space ones: a common exposure (smoking) demonstrably raises body cadmium; a plausible, testable molecular route from cadmium to neuronal mitochondrial impairment now exists in print; and the exposure itself — unlike the pathway — is already avoidable on evidence that long predates this paper.

Where the evidence stands

• Established: Cadmium exposure is linked to cognitive decline and Alzheimer's risk; smoking raises body cadmium burden; mitochondrial complex I dysfunction is a recognized feature of Alzheimer's disease biology; and JNK-family stress kinases respond to toxicant stress in neurons.
• Preliminary: In NHANES survey-weighted analysis, brain transcriptomics/single-nucleus data, human brain tissue and neuron experiments (J Transl Med, Nov 3, 2026; DOI 10.1186/s12967-026-09105-x), ever-smoking tracked with higher blood cadmium; MAPK9/JNK2 was nominated and enriched in excitatory neurons with amyloid-linked complex I dysfunction; JNK2 phosphorylation was increased in Alzheimer's brain; and cadmium chloride raised JNK2 phosphorylation and APP and impaired mitochondria in neurons, with sanguinarine docking stably to MAPK9.
• Absent: Any causal proof that cadmium exposure causes Alzheimer's disease in humans, longitudinal exposure-to-disease data, and any clinical evidence for sanguinarine or JNK2 inhibition.